Ekman G, Andersson K E, Rud T, Ulmsten U
Acta Pharmacol Toxicol (Copenh). 1980;46 Suppl 1:39-43. doi: 10.1111/j.1600-0773.1980.tb03246.x.
In a double-blind, cross-over study, the effects of terodiline were evaluated in 12 women with motor urge incontinence. The patients were investigated by simultaneous urethro-cystometry before and after treatment fo 2-week periods with placebo and terodiline 12.5 mg twice daily. The effects on subjective symptoms were also assessed. In all patients but one, terodiline increased the bladder capacity and also the bladder volume at which urgency was experienced. No effects on the urethral pressure profile or residual urine were found. Subjective improvement was reported by all but one of the patients. Placebo treatment had no effect on the measured parameters or on the subjective symptoms. No side effects were reported during any of the treatment periods. --It is concluded that terodiline can be used for treatment of female motor urge incontinence, and that it is a promising alternative to drugs presently used for this disorder.
在一项双盲交叉研究中，对12名患有运动性急迫性尿失禁的女性评估了特罗地林的效果。在接受安慰剂和每日两次12.5毫克特罗地林治疗2周前后，通过同步尿道膀胱测压法对患者进行了检查。还评估了对主观症状的影响。除一名患者外，在所有患者中，特罗地林增加了膀胱容量以及出现尿急时的膀胱容积。未发现对尿道压力曲线或残余尿量有影响。除一名患者外，所有患者均报告主观症状有所改善。安慰剂治疗对所测参数或主观症状均无影响。在任何治疗期间均未报告有副作用。——得出的结论是，特罗地林可用于治疗女性运动性急迫性尿失禁，并且它是目前用于该疾病的药物的一种有前景的替代药物。
